Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.

Arthritis Research & Therapy
Mark C GenoveseGerd R Burmester

Abstract

The interleukin-6 receptor inhibitor sarilumab demonstrated efficacy in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy in patients with moderately to severely active rheumatoid arthritis (RA) with an inadequate response (IR) or intolerant (INT) to methotrexate (MTX) or tumour necrosis factor (TNF)-α inhibitors. This analysis investigated the efficacy and safety of sarilumab in patient subgroups. Data were included from phase III studies: two placebo-controlled studies of subcutaneous sarilumab 150/200 mg every 2 weeks (q2w) either + MTX in MTX-IR patients (52 weeks) or + csDMARDs in TNF-IR/INT patients (24 weeks), and a monotherapy study of sarilumab 200 mg q2w vs. adalimumab 40 mg q2w in MTX-IR/INT patients (24 weeks). Prespecified and post hoc subgroups included patient demographics, disease characteristics, and prior treatments. Prespecified and post hoc endpoints included clinical, radiographic, and physical function measures, and p values are considered nominal. Safety was assessed during double-blind treatment. The superiority of sarilumab (either as monotherapy vs. adalimumab or in combination with csDMARDs vs. placebo + csDMARDs) across clinical endpoints was g...Continue Reading

References

Mar 14, 2003·Rheumatology International·Ioannis A PapadopoulosAlexandros A Drosos
Jan 20, 2004·Arthritis and Rheumatism·Jörg J GoronzyCornelia M Weyand
Nov 23, 2007·The New England Journal of Medicine·Rui WangJeffrey M Drazen
Sep 6, 2008·Arthritis Research & Therapy·Natacha CourvoisierBernard Combe
Nov 21, 2009·QJM : Monthly Journal of the Association of Physicians·Y W Song, E H Kang
Apr 1, 2010·BMJ : British Medical Journal·Xin SunGordon H Guyatt
Jul 27, 2012·Arthritis Care & Research·Jessica WiddifieldClaire Bombardier
Jun 7, 2013·Annals of the Rheumatic Diseases·A ZinkA Strangfeld
Jul 8, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Anaïs GardettePhilippe Dieudé
Dec 2, 2014·Rheumatic Diseases Clinics of North America·Jeffrey A Sparks, Karen H Costenbader
Oct 1, 2015·Annals of the Rheumatic Diseases·Daniel AletahaJosef S Smolen
Nov 8, 2015·Arthritis & Rheumatology·Jasvinder A SinghTimothy McAlindon
Jan 1, 2016·Current Opinion in Rheumatology·William H Robinson, Rong Mao
Jun 9, 2016·Rheumatology International·Emilio Martin-MolaEstíbaliz Loza
Aug 11, 2016·BMC Musculoskeletal Disorders·Soo-Kyung ChoSang-Cheol Bae
Nov 3, 2016·The Journal of Rheumatology·Atsuko MurotaTsutomu Takeuchi
Jun 24, 2019·Annals of the Rheumatic Diseases·Xanthe Me MatthijssenAnnette Hm van der Helm-van Mil

❮ Previous
Next ❯

Methods Mentioned

BETA
ESR

Clinical Trials Mentioned

NCT01061736
NCT01709578
NCT02332590

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.